Digital immunohistochemistry: new horizons and practical solutions in breast cancer pathology
© Laurinavicius et al; licensee BioMed Central Ltd. 2013
Published: 30 September 2013
Skip to main content
© Laurinavicius et al; licensee BioMed Central Ltd. 2013
Published: 30 September 2013
Digital image analysis (DA) brings new opportunities to enhance breast cancer pathology testing by providing tools to read tissue-based visual data in a more precise, accurate, and high-throughput manner compared to traditional evaluation performed by a pathologist. The applications may vary from very practical computer-assisted diagnosis approaches to obtain more reproducible estimates of biomarker expression to more sophisticated efforts to retrieve and aggregate multi-modal and multi-dimensional data providing integrated metamarkers of the disease [1, 2].
Immunohistochemistry (IHC) biomarkers are widely used for breast cancer categorization and provide basis for therapeutic decisions , therefore, standardization of IHC testing is of great importance. Applying DA tools for post-analytical IHC phase generates continuous data of broad dynamic range and can be used to analyse variance of the biomarker expression in more powerful statistical models and achieve better reproducibility. Also, analytical phase of IHC testing may also benefit from DA-based quality control systems. Another particular aspect of breast cancer diagnosis is related to HER2 gene and protein assays where better quantification systems are needed to resolve issues of tumours with equivocal and discordant HER2 status, potentially related to heterogeneity of tumour cell populations .
We hereby summarize our recent experiments to explore the advantages of DA for breast cancer pathology diagnosis and retrieval of new quality information based on IHC and FISH tests: DA-based quality monitor of tissue controls used for routine HER2 IHC testing, feasibility of DA to obtain automated cell-based HER2 FISH data, and the potential of factor analysis of the DA-generated IHC multi-marker expression data set to understand breast cancer immunoprofile variation.
For DA-based quality monitor, IHC tissue controls represented by consecutive serial sections (n=91) of formalin-fixed paraffin-embedded multi-blocks containing 2 mm diameter cores from 4 different tumour samples (HER2 IHC score 0, 1+, 2+, 3+) were used for routine HER2 IHC staining (Ventana Benchmark XT, Ventana Medical Systems, Tucson, Arizona, USA) one control section per batch. The stained sections were scanned (Aperio ScanScope XT at 20x objective magnification) and submitted for routine quality review of the staff in charge. DA (Aperio Genie and Membrane algorithms) on each spot was performed on “per-batch” basis; the control sections were then reviewed by a pathologist to estimate potential HER2 staining intensity variation. Batch-to-batch variation of IHC average membrane staining intensity, number of tumour cells, and percentage of tumour cells with complete membranous staining was examined and compared to the visual evaluation results.
For automated HER2 FISH data, tissue microarray (TMA) 4 μm-thick sections were stained with Vysis HER2 FISH kit (as described previously ); 38 digital images from 19 patients with ductal breast carcinoma were obtained from TissueFAXS (TissueGnostics GmbH, Vienna, Austria) using 63x oil objective and extended focus option in 9 Z planes set at 0.45 μm interval between the planes; the Z stack images were then projected into 2D images. TissueQuest version 4 (TissueGnostics GmbH) DA with the DotFinder v.4 algorithm was used to detect the FISH signals. By using the gating feature of the TissueQuest software, analysis was restricted to cell populations with non-overlapping nuclei to obtain cell-based FISH results. Two observers performed conventional microscope FISH analysis (40 cells per patient) according to Food and Drug Administration scoring system. The same microscope and objective was used for the visual evaluation and digital image acquisition.
Factor analysis of the DA-generated IHC multi-marker expression data was performed on tissue microarrays (TMA) of ductal carcinoma samples from 109 patients stained for 10 IHC markers as recently reported .
Statistical analyses were performed with SAS 9.2 software.
Digital image analysis outputs and pathologist’s IHC HER2 score on the IHC multi-block tissue controls
Core #1 HER2 0
Core #2 HER2 1+
Core #3 HER2 2+
Core #4 HER2 3+
Cores #1-4 Mean
Mean membrane intensity*
176 ± 16
190 ± 7
155 ± 11
86 ± 11
152 ± 8
% of cells with complete membranous staining*
1 ± 4
2 ± 5
17 ± 6
59 ± 6
19 ± 4
Total number of cells*
4277 ± 3205
6759 ± 3342
17536 ± 3382
19803 ± 4269
12094 ± 2778
Pathologist’s HER2 staining intensity score corresponding the expected category**
The DA-based HER2 IHC quality monitor provided a measurement of IHC staining quality useful in two aspects: as a quality control tool to alert on unexpected variation prospectively and as a quality improvement measure disclosing potential assay drifts based on retrospective analysis of the data. Although the use of DA to improve analytical phase of the IHC test has been suggested , we were not able to find published data on practical solutions. In our study, the DA parameters analysed on “per batch” basis revealed a rather broad IHC staining intensity variation underestimated by microscope-based IHC quality control review, while only a few cases with potential quality issues were detected by additional retrospective pathologist’s review.
The application of DA for IHC quality monitor is not as straightforward as it may appear. Several methodological issues have to be considered with caution. Although the same DA algorithm was used for the series, the impact of the tissue variation does not allow for a “pure” IHC tissue control system where, ideally, always an identical tissue section would be used as a reference. Although serial sections are expected to provide rather continuous changes of the tissue properties, cutting and other artefacts may impact the DA results. Furthermore, in our experiment we used a sophisticated DA algorithm, based on automated tumour tissue recognition, which may be dependent on section thickness, hematoxylin staining variation, etc. For this matter, the use of IHC multi-controls containing 4 different tumour samples could be regarded as an “internal control” for tissue-related DA variation, however, further optimization of the approach is needed.
Strong correlation was observed between the numbers of microscope- and DA-estimated HER2 and CEP17 signals/cell (r=0.83, p<0.0001 and r=0.68, p<0.002, retrospectively), and HER2/CEP17 ratio (r=0.71, p=0/0006); the corresponding correlations between two microscope evaluations was close to perfect. However, ANOVA analysis revealed significant bias to lower values of the DA-counted HER2 signals when compared to the microscope evaluation (average difference 1.35, CI 0.4-2.3, p<0.05). Meanwhile, no significant difference was observed between the methods when comparing CEP17 signal counts and HER2/CEP17 ratio.
We present our initial data on the DotFinder algorithm to detect HER2 and CEP17 signals, which is followed by other TissueQuest functionalities to select populations of non-overlapping tumour cells in paraffin sections. Although the final aim of the analysis is to achieve an automated cell-based quantification of the FISH signals providing a robust and high-throughput tool to investigate tumour tissue heterogeneity, in this first stage of validation, we have explored the accuracy of the signal detection. One major obstacle to achieve full automation of the analysis is related to spatial clustering of HER2 signals in some amplified cases; other algorithms (e.g., AutoVysion, Metafer) switch to area-based estimate of the “clusters” [8, 9]. This latter approach is clinically valid to detect amplified cases, however, to investigate intratumoral heterogeneity, a cell-based measurement providing actual number of FISH signals would be preferable. In our experiment, we did not include the “cluster” cases detected by conventional microscope evaluation, nevertheless, underestimation of the HER2 (but not CEP17) signal is likely to be related to spatial confluence of the signals in some HER2-amplified cells. Since the images for the analyses are produced by projecting 9 Z-stack images into one, some information allowing better signal discrimination is inevitably lost. We therefore suggest that with the increase in computing and storage capacity, 3-dimensional FISH-detection algorithms may be the basic way to progress further.
We have recently published  a study on breast cancer TMA stained for 10 IHC markers proving a concept that important biological interdependencies can be detected at the level of tumour tissue immunophenotype based on the factor analysis of DA data. This “automated readout” of the IHC data in the TMA revealed independent biological processes standing behind the IHC profile variability in the disease entities. Integral characteristics (factor scores) of individual patients were associated with main conventional categories of the breast ductal carcinoma. In particular, we found that major factor of the IHC profile variation was characterized by a strong inverse relation between the expression of hormone (estrogen, progesteron, androgen) receptors along with anti-apoptotic marker BCL2, on one side, and Ki67 (proliferation) and HIF-1α (hypoxic stress, angiogenesis) on the other side. We named this factor the “i-Grade” since its pattern reflected the interdependent variance of the IHC markers known to represent the axis from aggressive (Ki67, HIF-1α) to more indolent (hormone receptor-positive, BCL2) behaviour of the disease and was associated with the Nottingham histological grade. Also, we were able to test independent informative value of conventional and less explored IHC biomarkers and their combinations.
In summary, we report on three DA approaches expanding horizons of tissue-based breast cancer research and clinical practice. We used standard IHC and FISH techniques and commercially available DA tools to retrieve new aspects of information that can be used to enhance quality assurance and understanding of breast cancer pathology.
digital image analysis
the human epidermal growth factor receptor 2
fluorescence in situ hybridization
This work was partly supported by the Lithuanian Science Council Student Research Fellowship Award (JD). The authors thank Kestutis Mikalajunas for his excellent work with the Aperio Scanscope XT system and the TissueGnostics team for their professionalism and support.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.